No matter where Brilacidin stands in the study, it is unique and IMO would be hard pressed to be compared to any other drug on the list as it is part of a new arm of medicine, a DHP mimetic, small molecule, with a unique history of design and formulation resulting from years of high speed computer modeling.

Now add in it's safety profile, cost, and immunotherapeutic properties and it stands alone IMO.

The immuno... is so important because some of the listed drugs may be able to stop CV from killing the patient, but are they actually killing the virus so that long term problems that arise because of it and are prevented by Brilacidin since the virus is killed and has no chance to affect the body on down the road.

Not saying there may be a diamond in the rough out there, but IMO we are sitting on a giant gem of our own. It has been discovered, it has been made known, but the general public is still clueless as to it and its properties - and BP certainly doesn't want anyone knowing about it until one of them has the ability to partner the franchise. During the time of those discussions (after the CV trial and UC trial IMO) will be the real fun time for IPIX stockholders IMO.